Literature DB >> 9559342

Allelotyping demonstrates common and distinct patterns of chromosomal loss in human lung cancer types.

A K Virmani1, K M Fong, D Kodagoda, D McIntire, J Hung, V Tonk, J D Minna, A F Gazdar.   

Abstract

Allelic loss is a hallmark of tumor suppressor gene (TSG) inactivation. We have allelotyped 29 paired lymphoblastoid and lung cancer cell lines derived from 11 patients with small cell (SCLC) and 18 patients with non-small cell lung carcinomas (NSCLC). Statistical analysis indicated that a threshold of 30% separated non-random allelic loss from the random genetic deletions of malignancy. We have identified non-random allelic loss at 42 of 54 (78%) specific chromosomal regions examined, with 22 regions (52%) common between the two major lung cancer histologic types. There were 3 regions (7%) with allelic loss specific for SCLC and 17 regions (41%) specific for NSCLC. Furthermore, there were significant differences in loss of heterozygosity (LOH) frequencies between NSCLC and SCLC at 13 regions on eight chromosome arms (3p, 5q, 6q, 9p, 10q, 11p, 13q, and 19p). Eight homozygous deletions were present in seven cell lines at four regions, 3p12, 3p14.2, 9p21, and 10q23-25. We have also identified novel sites of chromosomal deletions. In particular, there was frequent loss at 11p13 in SCLC and loss at 6p21.3 and 13q12.3 in NSCLC. In this study, we demonstrate that a) non-random allelic losses in lung cancer involve multiple regions; b) some losses are common to both NSCLC and SCLC subtypes, whereas others are subtype specific; c) there are genetic deletions at novel chromosomal regions; and d) several homozygous deletions have been noted. Our studies demonstrate the usefulness of continuous cell lines for detailed allelotyping, for comparing genetic abnormalities between SCLC and NSCLC, and for identifying homozygous deletions.

Entities:  

Mesh:

Year:  1998        PMID: 9559342     DOI: 10.1002/(sici)1098-2264(199804)21:4<308::aid-gcc4>3.0.co;2-2

Source DB:  PubMed          Journal:  Genes Chromosomes Cancer        ISSN: 1045-2257            Impact factor:   5.006


  35 in total

Review 1.  The role of LKB1 in lung cancer.

Authors:  Montse Sanchez-Cespedes
Journal:  Fam Cancer       Date:  2011-09       Impact factor: 2.375

2.  Is caspase-8 a neuroendocrine lung tumor suppressor?

Authors:  Suparna Mazumder; Alexandru Almasan
Journal:  Cancer Biol Ther       Date:  2002 Jan-Feb       Impact factor: 4.742

3.  Ordered subset analysis identifies loci influencing lung cancer risk on chromosomes 6q and 12q.

Authors:  Shenying Fang; Susan M Pinney; Joan E Bailey-Wilson; Mariza A de Andrade; Yafang Li; Elena Kupert; Ming You; Ann G Schwartz; Ping Yang; Marshall W Anderson; Christopher I Amos
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2010-10-28       Impact factor: 4.254

Review 4.  Pathogenesis of lung cancer: 100 year report.

Authors:  York E Miller
Journal:  Am J Respir Cell Mol Biol       Date:  2005-09       Impact factor: 6.914

5.  High-resolution chromosome 3p allelotyping of breast carcinomas and precursor lesions demonstrates frequent loss of heterozygosity and a discontinuous pattern of allele loss.

Authors:  A Maitra; I I Wistuba; C Washington; A K Virmani; R Ashfaq; S Milchgrub; A F Gazdar; J D Minna
Journal:  Am J Pathol       Date:  2001-07       Impact factor: 4.307

Review 6.  Lung cancer cell lines: Useless artifacts or invaluable tools for medical science?

Authors:  Adi F Gazdar; Boning Gao; John D Minna
Journal:  Lung Cancer       Date:  2010-01-15       Impact factor: 5.705

Review 7.  Genomic imprinting and cancer.

Authors:  J A Joyce; P N Schofield
Journal:  Mol Pathol       Date:  1998-08

8.  Allelic imbalance regions on chromosomes 8p, 17p and 19p related to metastasis of hepatocellular carcinoma: comparison between matched primary and metastatic lesions in 22 patients by genome-wide microsatellite analysis.

Authors:  Lian-Hai Zhang; Lun-Xiu Qin; Zeng-Chen Ma; Sheng-Long Ye; Yin-Kun Liu; Qing-Hai Ye; Xin Wu; Wei Huang; Zhao-You Tang
Journal:  J Cancer Res Clin Oncol       Date:  2003-05-07       Impact factor: 4.553

Review 9.  Circulating tumor cells and CDX models as a tool for preclinical drug development.

Authors:  Alice Lallo; Maximilian W Schenk; Kristopher K Frese; Fiona Blackhall; Caroline Dive
Journal:  Transl Lung Cancer Res       Date:  2017-08

10.  MYO18B, a candidate tumor suppressor gene at chromosome 22q12.1, deleted, mutated, and methylated in human lung cancer.

Authors:  Michiho Nishioka; Takashi Kohno; Masachika Tani; Nozomu Yanaihara; Yoshio Tomizawa; Ayaka Otsuka; Shigeru Sasaki; Keiko Kobayashi; Toshiro Niki; Arafumi Maeshima; Yoshitaka Sekido; John D Minna; Saburo Sone; Jun Yokota
Journal:  Proc Natl Acad Sci U S A       Date:  2002-09-03       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.